Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 10/20 | 0.51 |
| ▸ | JAK1 | P23458 | 9/20 | 0.51 |
| ▸ | CDK2 | P24941 | 6/20 | 0.51 |
| ▸ | CDK1 | P06493 | 5/20 | 0.51 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.51 |
| ▸ | CDK9 | P50750 | 4/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.44 |
| ▸ | CDK7 | P50613 | 2/20 | 0.44 |
| ▸ | CCNH | P51946 | 2/20 | 0.44 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1473525 | 0.95 | CDK2 (0.52) | JAK3JAK1CDK2CDK1CCNE2 | |
| SCHEMBL1474911 | 0.93 | CDK2 (0.47) | JAK3JAK1CDK2CDK1CCNE2 | |
| SCHEMBL1474529 | 0.92 | JAK3 (0.53) | JAK3JAK1CDK2CDK1CCNE2 | |
| SCHEMBL1476223 | 0.92 | JAK3 (0.57) | JAK3JAK1CDK2CDK1CCNE2 | |
| SCHEMBL1474967 | 0.89 | JAK3 (0.51) | JAK3JAK1CDK2CDK1CCNE2 | |
| SCHEMBL1475126 | 0.88 | CDK2 (0.49) | JAK3JAK1CDK2CDK1CCNE2 | |
| SCHEMBL4001971 | 0.88 | CDK2 (0.58) | JAK3JAK1CDK2CDK1CCNE2 | |
| SCHEMBL3999779 | 0.87 | JAK3 (0.51) | JAK3JAK1CDK2CDK1CCNE2 | |
| SCHEMBL1474385 | 0.87 | JAK3 (0.59) | JAK3JAK1CDK2CDK1CCNE2 | |
| SCHEMBL1475976 | 0.86 | CDK1 (0.52) | JAK3JAK1CDK2CDK1CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221089-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | claimed |
| US-20070203161-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | claimed |
| US-11667611-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20190256476-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-20170121291-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-9593082-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-7915273-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100152218-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20080221089-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008079907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20070203161-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667611-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885CDK2 236/4885 |
| US-20170121291-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885CDK2 236/4885 |
| US-20190256476-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885CDK2 236/4885 |
| US-20070203161-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885CDK2 236/4885 |
| US-20080221089-A1 | Prevent transplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | JAK3 1/4885JAK1 2/4885CDK2 986/4885 |
| US-20100152218-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885CDK2 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.